Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2024-07-22 Capital/Financing Update
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price of convertible bonds due to a decline in the company's stock price. This type of filing, which details changes to the capital structure and financial instruments (specifically convertible debt), falls under the 'Capital/Financing Update' category. It is not a report publication announcement, but rather the primary disclosure of the financial event itself.
2024-07-22 Korean
기타경영사항(자율공시)
M&A Activity Classification · 100% confidence The document is a short regulatory filing (under 5,000 characters) from a Korean company (Pangen) regarding the outcome of a board meeting and the cancellation of a potential merger due to the counterparty's delisting. Since it is a general regulatory announcement regarding corporate management decisions that does not fit into specific categories like M&A (as it is a cancellation notice) or Board changes, it falls under the RNS category.
2024-06-21 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Pangen) regarding a 'Single Sale/Supply Contract' amendment. It details a change in the contract end date for a pharmaceutical supply agreement. Since this is a specific corporate announcement regarding a contract amendment that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-06-11 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'PanGen' (주)팬젠, covering the period from 2024.01.01 to 2024.03.31. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a regulatory filing required under Article 147 of the Capital Markets Act in South Korea. This document details changes in share ownership (specifically by Huons Co., Ltd. and its related parties in Pangen Co., Ltd.) due to third-party allotment and market purchases. Since this is a mandatory disclosure of significant shareholding thresholds, it falls under the 'Major Shareholding Notification' category.
2024-04-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in South Korea. This type of filing is required when a major shareholder or executive changes their stake in a company. In the provided text, Huons Co., Ltd. is reporting a change in its shareholding of Pangen Co., Ltd. due to a third-party capital increase. This falls under the category of 'Major Shareholding Notification' (MRQ) as it details the change in significant share ownership levels.
2024-04-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.